La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Centessa Pharmaceuticals Bilan de santé

Santé financière contrôle des critères 5/6

Centessa Pharmaceuticals possède un total de capitaux propres de $287.0M et une dette totale de $76.5M, ce qui porte son ratio d'endettement à 26.7%. Son actif total et son passif total sont $398.8M et de $111.9M.

Informations clés

26.7%

Ratio d'endettement

US$76.50m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$294.83m
Fonds propres	US$286.97m
Total du passif	US$111.88m
Total des actifs	US$398.85m

Mises à jour récentes de la santé financière

Centessa Pharmaceuticals (NASDAQ:CNTA) Has Debt But No Earnings; Should You Worry?

Aug 15

Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?

Mar 07

Recent updates

Centessa Pharmaceuticals: Progressing SerpinPC Through Registrational Trials In Hemophilia B

Sep 25

Centessa Pharmaceuticals (NASDAQ:CNTA) Has Debt But No Earnings; Should You Worry?

Aug 15

Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point

Apr 24

Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?

Mar 07

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de CNTA ( $355.5M ) dépassent ses passifs à court terme ( $26.8M ).

Passif à long terme: Les actifs à court terme de CNTA ( $355.5M ) dépassent ses passifs à long terme ( $85.1M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: CNTA dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Données insuffisantes pour déterminer si le ratio d'endettement de CNTA a diminué au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: CNTA dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: CNTA dispose d'une marge de trésorerie suffisante pour 1.7 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 32.3 % chaque année.

Centessa Pharmaceuticals Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Centessa Pharmaceuticals (NASDAQ:CNTA) Has Debt But No Earnings; Should You Worry?

Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?

Recent updates

Chief Business Officer recently sold US$261k worth of stock

Centessa Pharmaceuticals: Progressing SerpinPC Through Registrational Trials In Hemophilia B

CEO & Director notifies of intention to sell stock

Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $150 million.

Chief Business Officer notifies of intention to sell stock

Price target increased by 10% to US$16.00

Centessa Pharmaceuticals plc Announces Positive Interim Phase 1 Clinical Data with Its Novel Orexin Receptor 2 (OX2R) Agonist, Orx750, in Acutely Sleep-Deprived Healthy Volunteers

CEO & Director notifies of intention to sell stock

Centessa Pharmaceuticals (NASDAQ:CNTA) Has Debt But No Earnings; Should You Worry?

Price target increased by 9.2% to US$14.20

Centessa Pharmaceuticals plc Announces Chief Financial Officer Changes

Insufficient new directors

Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $100 million.

Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $100 million.

Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point

Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $100 million.

Centessa Pharmaceuticals plc Announces Open IND for ORX750

Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?

New major risk - Revenue and earnings growth

Centessa Pharmaceuticals plc Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2A Study of Serpinpc for the Treatment of Hemophilia

Centessa Pharmaceuticals plc Announces Dosing of First Subject in Registrational Present-3 Study Evaluating Serpinpc for the Treatment of Hemophilia B with Inhibitors

Centessa Pharmaceuticals plc Announces Preclinical Data Supporting Orx750's Potential as A Best-In-Class Oral Ox2r Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders

Insider notifies of intention to sell stock

World Sleep Congress Releases an Abstract Submit by Centessa Pharmaceuticals plc

New major risk - Revenue and earnings growth

Price target increased by 18% to US$7.08

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B Without Inhibitors

New minor risk - Share price stability

Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for Serpinpc for Hemophilia B

Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors

Centessa Pharmaceuticals plc Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension of Phase 2a Study of SerpinPC for Hemophilia

Centessa Pharmaceuticals Announces Karen Anderson as New Chief People Officer

Price target decreased to US$6.00

High number of new and inexperienced directors

The Law Offices of Vincent Wong Announces Class Action Lawsuit Against Centessa Pharmaceuticals plc

Centessa Pharmaceuticals snaps multi-day losing streak; up 10%

Centessa Pharmaceuticals plc Announces Departure of Javad Shahidi as Chief Medical Officer

Centessa Pharmaceuticals plc Announces Class Action Lawsuit Against Centessa Pharmaceuticals plc

Centessa hemophilia B therapy SerpinPC gets FDA orphan drug status

Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) Demonstrating Potential for Enhanced Therapeutic Index

Centessa Pharmaceuticals GAAP EPS of -$0.69

Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, Phd, as Senior Vice President of Regulatory Affairs

Centessa Pharmaceuticals plc Announces Executive Changes

Centessa Pharmaceuticals plc Announces Board Changes

Centessa Pharmaceuticals plc Announces Poster Presentation of First Preclinical Data for LockBody Program At 2022 ASCO Annual Meeting

Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Centessa Pharmaceuticals plc, Annual General Meeting, Jun 30, 2022

High number of new and inexperienced directors

High number of new and inexperienced directors

Centessa Pharmaceuticals Doses First Subject in Global Phase 3 Action Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease

Centessa Pharmaceuticals Limited Announces Resignation of Robert M. Califf as Member of the Board of Directors

Checking In On Centessa Pharmaceuticals

Centessa Pharmaceuticals plc Together with Subsidiary Palladio Biosciences, Inc. Initiates Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease and Reports Initial Positive Safety Data from ALERT Study

Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not on Prophylaxis

Centessa Pharmaceuticals stock pops 20%+ intraday to post-IPO high

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines